Streptomyces-Derived Nano-Doxorubicin: Clinical Status and Patents Granted

Streptomyces-derived doxorubicin (DOX) is a widely used anti-cancer drug effective against various cancers but is limited by significant adverse effects such as nausea, vomiting, alopecia, and cardiotoxicity. Nanoparticle delivery systems offer a promising solution to mitigate these side effects, with some formulations already in clinical use and others showing potential in development. This review emphasizes the importance of integrating nanotechnology with Streptomyces-derived compounds to enhance anti-cancer therapies, highlighting the current clinical status and the need for further development of multifunctional nanoparticles.